

Otago Innovation Ltd — University of Otago's Research Commercialisation Company

City Innovation Library · Good practice · New Zealand

Quality score: 43/100

Evidence strength: Moderate

Summary

The University of Otago's wholly-owned commercialisation company. A 2009 report found it fell far short of royalty targets, but by 2021 it co-led its largest-ever deal: a \$14M raise for cancer-therapy spin-out Amaroq Therapeutics.

Key dimensions

Dimension	Score
Innovation	1/3
Inclusiveness / equity	0/3
Evidence of impact / measured results	2/3
Transferability / demonstrated replication	1/3
Scalability	1/3
Sustainability / continuity	2/3
Multi-stakeholder collaboration	2/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-07-23

[Otago Innovation Ltd / University of Otago](#) — accessed 2026-07-23

[Otago Innovation official site](#) — accessed 2026-07-23

[Otago Daily Times — Otago Innovation yield drops \(2009\)](#) — accessed 2026-07-23

[University of Otago newsroom — \\$14m invested in world-leading RNA therapy \(2021\)](#) — accessed 2026-07-23

Cite this — Evidoria. *Otago Innovation Ltd — University of Otago's Research Commercialisation Company*. Persistent ID: f780a1ce-3b36-432c-8735-5bb0d710bfc7.